{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,6]],"date-time":"2026-10-06T05:29:15Z","timestamp":1791264555196,"version":"4.1.0"},"reference-count":41,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2014,11,1]],"date-time":"2014-11-01T00:00:00Z","timestamp":1414800000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"funder":[{"name":"French Association for Cancer Research","award":["ECL2010R00778"],"award-info":[{"award-number":["ECL2010R00778"]}]},{"name":"Novartis Pharma (Grant 2006\/051\/Novartis Rueil-Malmaison, France)"}],"content-domain":{"domain":["thebonejournal.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Bone"],"published-print":{"date-parts":[[2014,11]]},"DOI":"10.1016\/j.bone.2014.08.018","type":"journal-article","created":{"date-parts":[[2014,9,2]],"date-time":"2014-09-02T18:48:44Z","timestamp":1409683724000},"page":"146-152","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":29,"special_numbering":"C","title":["Preclinical evidence of potential craniofacial adverse effect of zoledronic acid in pediatric patients with bone malignancies"],"prefix":"10.1016","volume":"68","author":[{"given":"Fr\u00e9d\u00e9ric","family":"L\u00e9zot","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Julie","family":"Chesneau","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"S\u00e9verine","family":"Battaglia","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"R\u00e9gis","family":"Brion","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Beatriz","family":"Castaneda","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jean-Christophe","family":"Farges","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dominique","family":"Heymann","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3644-7627","authenticated-orcid":false,"given":"Fran\u00e7oise","family":"R\u00e9dini","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.bone.2014.08.018_bb0005","doi-asserted-by":"crossref","first-page":"2961","DOI":"10.1002\/1097-0142(20000615)88:12+<2961::AID-CNCR12>3.0.CO;2-L","article-title":"Cellular and molecular mechanisms of action of bisphosphonates","volume":"88","author":"Rogers","year":"2000","journal-title":"Cancer"},{"key":"10.1016\/j.bone.2014.08.018_bb0010","doi-asserted-by":"crossref","first-page":"367","DOI":"10.1196\/annals.1346.041","article-title":"Bisphosphonates: from bench to bedside","volume":"1068","author":"Russell","year":"2006","journal-title":"Ann N Y Acad Sci"},{"key":"10.1016\/j.bone.2014.08.018_bb0015","doi-asserted-by":"crossref","first-page":"1189","DOI":"10.1056\/NEJMoa030897","article-title":"Ten years' experience with alendronate for osteoporosis in postmenoposal women","volume":"350","author":"Bone","year":"2004","journal-title":"N Engl J Med"},{"key":"10.1016\/j.bone.2014.08.018_bb0020","doi-asserted-by":"crossref","first-page":"337","DOI":"10.1016\/j.molmed.2004.05.007","article-title":"Bisphosphonates: new therapeutic agents for the treatment of bone tumors","volume":"10","author":"Heymann","year":"2004","journal-title":"Trends Mol Med"},{"key":"10.1016\/j.bone.2014.08.018_bb0025","doi-asserted-by":"crossref","first-page":"1235","DOI":"10.1359\/JBMR.050213","article-title":"Effects of intravenous pamidronate treatment in infants with osteogenesis imperfecta: clinical and histomorphometric outcome","volume":"20","author":"Munns","year":"2005","journal-title":"J Bone Miner Res"},{"key":"10.1016\/j.bone.2014.08.018_bb0030","doi-asserted-by":"crossref","first-page":"55","DOI":"10.1515\/JPEM.2009.22.1.55","article-title":"Safety and efficacy of intravenous zoledronic acid in paediatric osteoporosis","volume":"22","author":"Brown","year":"2009","journal-title":"J Pediatr Endocrinol Metab"},{"key":"10.1016\/j.bone.2014.08.018_bb0035","doi-asserted-by":"crossref","first-page":"753","DOI":"10.1136\/adc.2006.093997","article-title":"Systematic review of effectiveness of bisphosphonates in treatment of low bone mineral density and fragility fractures in juvenile idiopathic arthritis","volume":"91","author":"Thornton","year":"2006","journal-title":"Arch Dis Child"},{"key":"10.1016\/j.bone.2014.08.018_bb0040","doi-asserted-by":"crossref","first-page":"67","DOI":"10.1016\/j.tripleo.2006.09.021","article-title":"Remarkable response of juvenile diffuse sclerosing osteomyelitis of mandible to pamidronate","volume":"104","author":"Yamazaki","year":"2007","journal-title":"Oral Surg Oral Med Oral Pathol Oral Radiol Endod"},{"key":"10.1016\/j.bone.2014.08.018_bb0045","doi-asserted-by":"crossref","first-page":"3562","DOI":"10.1200\/JCO.2001.19.15.3562","article-title":"The biology of osteoclast activation in cancer","volume":"19","author":"Roodman","year":"2001","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.bone.2014.08.018_bb0050","doi-asserted-by":"crossref","first-page":"3451","DOI":"10.1158\/1078-0432.CCR-08-1616","article-title":"Zoledronic acid inhibits both the osteolytic and osteoblastic components of osteosarcoma lesions in a mouse model","volume":"15","author":"Labrinidis","year":"2009","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.bone.2014.08.018_bb0055","doi-asserted-by":"crossref","first-page":"255","DOI":"10.1038\/sj.bjc.6603548","article-title":"Combined effects of a third-generation bisphosphonate, zoledronic acid with other anticancer agents against murine osteosarcoma","volume":"96","author":"Horie","year":"2007","journal-title":"Br J Cancer"},{"key":"10.1016\/j.bone.2014.08.018_bb0060","doi-asserted-by":"crossref","first-page":"1713","DOI":"10.1002\/cncr.21383","article-title":"Zoledronic acid inhibits primary bone tumor growth in Ewing sarcoma","volume":"104","author":"Zhou","year":"2005","journal-title":"Cancer"},{"issue":"19","key":"10.1016\/j.bone.2014.08.018_bb0065","doi-asserted-by":"crossref","first-page":"7610","DOI":"10.1158\/0008-5472.CAN-09-4272","article-title":"Zoledronic acid as a new adjuvant therapeutic strategy for Ewing's sarcoma patients","volume":"70","author":"Odri","year":"2010","journal-title":"Cancer Res"},{"issue":"3","key":"10.1016\/j.bone.2014.08.018_bb0070","doi-asserted-by":"crossref","first-page":"475","DOI":"10.1007\/s00441-007-0499-y","article-title":"Effects of alendronate on tooth eruption and molar root formation in young growing rats","volume":"330","author":"Bradaschia-Correa","year":"2007","journal-title":"Cell Tissue Res"},{"issue":"1","key":"10.1016\/j.bone.2014.08.018_bb0075","doi-asserted-by":"crossref","first-page":"8","DOI":"10.1177\/00220345980770011201","article-title":"Inhibition of tooth eruption in the rat by a bisphosphonate","volume":"77","author":"Grier","year":"1998","journal-title":"J Dent Res"},{"issue":"6","key":"10.1016\/j.bone.2014.08.018_bb0080","doi-asserted-by":"crossref","first-page":"502","DOI":"10.1007\/s00223-010-9366-z","article-title":"Administration of the bisphosphonate zoledronic acid during tooth development inhibits tooth eruption and formation and induces dental abnormalities in rats","volume":"86","author":"Hiraga","year":"2010","journal-title":"Calcif Tissue Int"},{"issue":"3","key":"10.1016\/j.bone.2014.08.018_bb0085","doi-asserted-by":"crossref","first-page":"195","DOI":"10.1111\/j.1600-0722.2008.00529.x","article-title":"Effects of bisphosphonates on tooth eruption in children with osteogenesis imperfecta","volume":"116","author":"Kamoun-Goldrat","year":"2008","journal-title":"Eur J Oral Sci"},{"issue":"9","key":"10.1016\/j.bone.2014.08.018_bb0090","doi-asserted-by":"crossref","first-page":"519","DOI":"10.1055\/s-0031-1284365","article-title":"Paget's disease of bone and calcium homeostasis: focus on bisphosphonate treatment","volume":"119","author":"Polyzos","year":"2011","journal-title":"Exp Clin Endocrinol Diabetes"},{"issue":"17","key":"10.1016\/j.bone.2014.08.018_bb0095","doi-asserted-by":"crossref","first-page":"3721","DOI":"10.1021\/jm020819i","article-title":"Highly potent geminal bisphosphonates. From pamidronate disodium (Aredia) to zoledronic acid (Zometa)","volume":"45","author":"Widler","year":"2002","journal-title":"J Med Chem"},{"issue":"10","key":"10.1016\/j.bone.2014.08.018_bb0100","doi-asserted-by":"crossref","first-page":"2439","DOI":"10.1002\/jbmr.453","article-title":"Impact of oncopediatric dosing regimen of zoledronic acid on bone growth: preclinical studies and case report of an osteosarcoma pediatric patient","volume":"26","author":"Battaglia","year":"2011","journal-title":"J Bone Miner Res"},{"issue":"6","key":"10.1016\/j.bone.2014.08.018_bb0105","doi-asserted-by":"crossref","first-page":"458","DOI":"10.1038\/35076601","article-title":"Genetics of craniofacial development and malformation","volume":"2","author":"Wilkie","year":"2001","journal-title":"Nat Rev Genet"},{"issue":"2","key":"10.1016\/j.bone.2014.08.018_bb0110","doi-asserted-by":"crossref","first-page":"111","DOI":"10.1016\/S0925-4773(97)00115-9","article-title":"Signalling networks regulating dental development","volume":"67","author":"Thesleff","year":"1997","journal-title":"Mech Dev"},{"issue":"7","key":"10.1016\/j.bone.2014.08.018_bb0115","doi-asserted-by":"crossref","first-page":"911","DOI":"10.1517\/17425255.2011.585156","article-title":"Pharmacokinetic evaluation of zoledronic acid","volume":"7","author":"De Luca","year":"2011","journal-title":"Expert Opin Drug Metab Toxicol"},{"issue":"10","key":"10.1016\/j.bone.2014.08.018_bb0120","doi-asserted-by":"crossref","first-page":"2043","DOI":"10.1124\/dmd.108.021071","article-title":"Biodistribution and plasma protein binding of zoledronic acid","volume":"36","author":"Weiss","year":"2008","journal-title":"Drug Metab Distrib"},{"key":"10.1016\/j.bone.2014.08.018_bb0125","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1007\/978-1-4419-0284-9_1","article-title":"The epidemiology of osteosarcoma","volume":"152","author":"Ottaviani","year":"2009","journal-title":"Cancer Treat Res"},{"issue":"1","key":"10.1016\/j.bone.2014.08.018_bb0130","doi-asserted-by":"crossref","first-page":"1","DOI":"10.3109\/08880018.2011.622034","article-title":"Ewing sarcoma: clinical state-of-the-art","volume":"29","author":"Potratz","year":"2012","journal-title":"Pediatr Hematol Oncol"},{"issue":"27","key":"10.1016\/j.bone.2014.08.018_bb0135","doi-asserted-by":"crossref","first-page":"2981","DOI":"10.2174\/138161210793563554","article-title":"Therapeutic approach of primary bone tumours by bisphosphonates","volume":"16","author":"Moriceau","year":"2010","journal-title":"Curr Pharm Des"},{"issue":"20","key":"10.1016\/j.bone.2014.08.018_bb0140","doi-asserted-by":"crossref","first-page":"2126","DOI":"10.2174\/092986707781389600","article-title":"Zoledronic acid\u2014a multiplicity of anti-cancer action","volume":"14","author":"Yuasa","year":"2007","journal-title":"Curr Med Chem"},{"issue":"9","key":"10.1016\/j.bone.2014.08.018_bb0145","doi-asserted-by":"crossref","first-page":"851","DOI":"10.1016\/j.archoralbio.2009.06.002","article-title":"Zoledronic acid decreases bone formation without causing osteocyte death in mice","volume":"54","author":"Huja","year":"2009","journal-title":"Arch Oral Biol"},{"issue":"9","key":"10.1016\/j.bone.2014.08.018_bb0150","doi-asserted-by":"crossref","first-page":"713","DOI":"10.1111\/j.1600-0714.2012.01154.x","article-title":"Zoledronic acid suppresses mineralization through direct cytotoxicity and osteoblast differentiation inhibition","volume":"41","author":"Patntirapong","year":"2012","journal-title":"J Oral Pathol Med"},{"issue":"2","key":"10.1016\/j.bone.2014.08.018_bb0155","doi-asserted-by":"crossref","first-page":"115","DOI":"10.1016\/j.archoralbio.2004.11.016","article-title":"Osteoclast diseases and dental abnormalities","volume":"50","author":"Helfrich","year":"2005","journal-title":"Arch Oral Biol"},{"issue":"1","key":"10.1016\/j.bone.2014.08.018_bb0160","first-page":"39","article-title":"Malignant infantile osteopetrosis: dental effects in paediatric patients. Case reports","volume":"7","author":"Luzzi","year":"2006","journal-title":"Eur J Paediatr Dent"},{"issue":"2","key":"10.1016\/j.bone.2014.08.018_bb0165","doi-asserted-by":"crossref","first-page":"405","DOI":"10.1016\/j.joms.2010.05.025","article-title":"Cysts and tumors associated with impacted third molars: is prophylactic removal justified?","volume":"69","author":"Stathopoulos","year":"2011","journal-title":"J Oral Maxillofac Surg"},{"issue":"2","key":"10.1016\/j.bone.2014.08.018_bb0170","doi-asserted-by":"crossref","first-page":"234","DOI":"10.1177\/08959374890030022401","article-title":"Developmental disturbances of the rat molar induced by two diphosphonates","volume":"3","author":"Fouda","year":"1989","journal-title":"Adv Dent Res"},{"issue":"1","key":"10.1016\/j.bone.2014.08.018_bb0175","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1210\/en.2011-1439","article-title":"Increased numbers of nonattached osteoclasts after long-term zoledronic acid therapy in mice","volume":"153","author":"Kuroshima","year":"2012","journal-title":"Endocrinology"},{"issue":"1","key":"10.1016\/j.bone.2014.08.018_bb0180","doi-asserted-by":"crossref","first-page":"53","DOI":"10.1056\/NEJMoa0802633","article-title":"Giant osteoclast formation and long-term oral bisphosphonate therapy","volume":"360","author":"Weinstein","year":"2009","journal-title":"N Engl J Med"},{"issue":"11","key":"10.1016\/j.bone.2014.08.018_bb0185","doi-asserted-by":"crossref","first-page":"1473","DOI":"10.1038\/nm.2489","article-title":"Suppression of bone formation by osteoclastic expression of semaphorin 4D","volume":"17","author":"Negishi-Koga","year":"2011","journal-title":"Nat Med"},{"issue":"2","key":"10.1016\/j.bone.2014.08.018_bb0190","doi-asserted-by":"crossref","first-page":"109","DOI":"10.1007\/s11914-012-0096-1","article-title":"Intercellular cross-talk among bone cells: new factors and pathways","volume":"10","author":"Sims","year":"2012","journal-title":"Curr Osteoporos Rep"},{"issue":"1","key":"10.1016\/j.bone.2014.08.018_bb0195","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1016\/j.archoralbio.2007.08.005","article-title":"Semaphorin 4D inhibits collagen synthesis of rat pulp-derived cells","volume":"53","author":"Abe","year":"2008","journal-title":"Arch Oral Biol"},{"issue":"8","key":"10.1016\/j.bone.2014.08.018_bb0200","doi-asserted-by":"crossref","first-page":"447","DOI":"10.1111\/j.1600-0714.2007.00553.x","article-title":"Cranial suture biology and dental development: genetic and clinical perspectives","volume":"36","author":"De Coster","year":"2007","journal-title":"J Oral Pathol Med"},{"issue":"1","key":"10.1016\/j.bone.2014.08.018_bb0205","doi-asserted-by":"crossref","first-page":"74","DOI":"10.1002\/jcp.22305","article-title":"Bone resorption control of tooth eruption and root morphogenesis: involvement of the receptor activator of NF-kB (RANK)","volume":"226","author":"Castaneda","year":"2011","journal-title":"J Cell Physiol"}],"container-title":["Bone"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S8756328214003299?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S8756328214003299?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2019,8,14]],"date-time":"2019-08-14T11:56:17Z","timestamp":1565783777000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S8756328214003299"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2014,11]]},"references-count":41,"alternative-id":["S8756328214003299"],"URL":"https:\/\/doi.org\/10.1016\/j.bone.2014.08.018","relation":{},"ISSN":["8756-3282"],"issn-type":[{"value":"8756-3282","type":"print"}],"subject":[],"published":{"date-parts":[[2014,11]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Preclinical evidence of potential craniofacial adverse effect of zoledronic acid in pediatric patients with bone malignancies","name":"articletitle","label":"Article Title"},{"value":"Bone","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.bone.2014.08.018","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2014 Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}